Samraat S. Raha
Chief executive: Myriad Genetics Inc. (30 Apr 2025 to present)
5commitments announced
3with a clear outcome
3met on time
–rate shown after 15 outcomes
Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Myriad Genetics Inc. filing.
Commitments announced under Samraat S. Raha
| Myriad Genetics Inc.announced 20 Oct 2026 | Complete the sale of the Prenatal Health testing business to Labcorp | Open31 Mar 2027 |
| Myriad Genetics Inc.announced 23 Feb 2026 | Launch targeted alpha for Precise MRD breast cancer test | Met31 Mar 2026 |
| Myriad Genetics Inc.announced 3 Nov 2025 | Commercially launch its first AI-enabled prostate cancer test | Met30 Jun 2026 |
| Myriad Genetics Inc.announced 5 Aug 2025 | Launch the proprietary, ultra-sensitive MRD test | Met30 Jun 2026 |
| Myriad Genetics Inc.announced 5 Aug 2025 | Commercially launch the FirstGene Multiple Prenatal Screen | Open31 Dec 2026 |
Is this record wrong, or are you Samraat S. Raha? Add a statement or ask for a correction.